Movement?, page-3

From the last update:
Pre-clinical development of PAT-DX1 The Company has previously indicated that it anticipated announcing data from two pre-clinical studies in Q1, 2019 (PAT-DX1 plus radiation in a mouse model of triple negative breast cancer brain metastases, and PAT-DX1 plus radiation in a mouse model of glioblastoma). The first of these experiments is ongoing, and the second experiment can only commence after the first experiment is complete. Accordingly, we now expect to report the data from both studies in Q2, 2019. At this stage the Company still believes that it will be able to report on its third study (PAT-DX1 plus temazolamide in a mouse model of glioblastoma) before the end of H1, 2019.

7 weeks max hopefully. My last communication with Dr Campbell was specifically non-specific about Yale holding things up. Let's hope not so this time. MIO